No Data
No Data
TD Cowen Maintains IO Biotech(IOBT.US) With Buy Rating
Promising Clinical Progress and Financial Stability Drive Buy Rating for IO Biotech
IO Biotech | 10-Q: Q3 2024 Earnings Report
Express News | HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $12 Price Target
IO Biotech Analyst Ratings
Positive Outlook for IO Biotech Amid Promising Clinical Developments in Melanoma and Head & Neck Cancer Trials
No Data
No Data